Healthy High Growth Stocks With Strong Balance Sheets Investors May Be Missing

With inflation signals mixed across major economies, interest rates still a key driver of borrowing costs, and growth pockets emerging from Asia to Europe, investors increasingly want companies that can grow earnings while keeping their balance sheets in good shape. That is exactly what the Healthy high growth potential screener looks for by highlighting businesses where analysts expect strong earnings growth over the next 3 years and where financial foundations appear acceptable rather than stretched. In this article, you will see 3 stocks from this screener that show how this blend of growth potential and financial discipline can look in practice.

Overview: SELLAS Life Sciences Group is a late stage biopharmaceutical company headquartered in New York that is developing cancer treatments, led by its GPS immunotherapy targeting the WT1 antigen and its SLS009 CDK9 inhibitor, in partnership with groups like Merck, GenFleet Therapeutics and Memorial Sloan Kettering.

Market Cap: US$2.0b

SELLAS Life Sciences Group appears on many growth radars because analysts expect strong revenue and earnings expansion over the next few years, supported by late stage GPS trial work in acute myeloid leukemia and mid stage data from SLS009. The company is still loss making with rising losses and a high P/B multiple, and shareholders have recently faced significant dilution and share price volatility, so risk is clearly part of the story. At the same time, experienced management, deep oncology partnerships and speculation around potential corporate interest give this US$2.0b stock a profile that is quite different from early stage biotech peers and place significant importance on the upcoming GPS and SLS009 readouts.

SELLAS Life Sciences Group sits at the intersection of late stage cancer science, rising losses and high expectations, so it is worth seeing how analysts tie that story together in the analysis report for SELLAS Life Sciences Group

Overview: ARS Pharmaceuticals is a biopharmaceutical company based in San Diego that develops and commercializes neffy, a needle free intranasal epinephrine treatment for severe allergic reactions and anaphylaxis, with a focus on use in both adults and children in emergency settings.

Operations: ARS Pharmaceuticals currently generates about US$99 million in revenue from pharmaceuticals, with roughly US$81.9 million reported from the United States and the remainder from segment adjustments.

Market Cap: US$796.4m

Investors watching ARS Pharmaceuticals are considering a trade off between the potential scale of a global allergy and anaphylaxis franchise centred on neffy and the reality that the company relies heavily on a single product and is still loss making. Factors such as prescription growth potential and fresh approvals, including Health Canada’s approval for neffy, are balanced against recent share price weakness following setbacks in securing broader commercial insurance coverage and the need for high marketing and SG&A spending to build awareness. For investors willing to accept concentration and execution risks, the combination of a large unmet need, growing international reach and analyst expectations of faster growth than the wider US market may make ARS Pharmaceuticals a stock worth a closer look.

ARS Pharmaceuticals is trying to turn a single needle free allergy product into a global franchise, and the analyst forecasts for ARS Pharmaceuticals lays out how that story could evolve and where the biggest surprise might sit.

Overview: Iovance Biotherapeutics is a commercial stage biopharmaceutical company that develops and sells personalized cell therapies, including Amtagvi and Proleukin, to treat metastatic melanoma and other solid tumor cancers in the United States and internationally.

Operations: Iovance Biotherapeutics currently generates about US$285.6 million in revenue from developing and commercializing autologous tumor infiltrating lymphocyte therapies, with roughly US$281.0 million from the United States and the remainder from the rest of the world.

Market Cap: US$1.9b

Iovance Biotherapeutics provides exposure to a new approach to cancer treatment, with Amtagvi already commercial and recent approvals in markets such as Australia contributing to US revenue momentum. A broad TIL pipeline and partnerships with groups such as the NIH and Novartis create additional potential opportunities beyond metastatic melanoma. These prospects sit alongside risks related to ongoing losses, heavy reliance on a small product set, potential dilution from a higher share authorization, and tougher regulatory and reimbursement scrutiny for complex cell therapies. The balance between these opportunities and the funding and execution risks is central to the investment debate on Iovance Biotherapeutics.

Iovance Biotherapeutics is working to turn personalized TIL therapies into a real business, but the full story lies in how funding, pipeline, and execution fit together in the analysis report for Iovance Biotherapeutics

The three stocks in this article are only a small sample. The full screener surfaced 1,485 more companies with similar earnings growth potential and balance sheet profiles through the Healthy high growth potential screener. Use Simply Wall St to identify, filter, and analyze the specific catalysts and narratives that matter most so you can focus on the highest conviction opportunities for your portfolio.

Take Control of Your Investment Journey

If SELLAS Life Sciences Group or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen.
Once you’ve made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.
Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.
By uncovering hidden catalysts and risks early, you’ll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly

New breakout stories, early momentum and quietly dropping risks rarely stay under the radar for long, so scan these fresh stock ideas before the crowd catches on and act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com